Prestige Consumer Healthcare beats Q1 revenue estimates, raises 2027 outlook
PBH•Drivers of the quarter
- Category strength — Organic growth in Gastrointestinal and Dermatological categories contributed to Q1 revenue gains.
- Acquisition impact — The Breathe Right acquisition added $6 million to Q1 revenue.
- Working capital — Higher adjusted free cash flow was due to the timing of working capital.
Q1 results beat estimates
Prestige Consumer Healthcare said fiscal first-quarter revenue rose 6.5%, beating analyst expectations.
Adjusted diluted earnings per share for fiscal Q1 rose to $0.98 from $0.95 a year earlier.
Outlook raised on acquisitions
The company closed the Breathe Right and LaCorium acquisitions, raising its fiscal 2027 outlook.
Prestige Consumer Healthcare now expects fiscal 2027 revenue of $1.29 billion to $1.315 billion, including acquisitions. It expects adjusted diluted EPS of $4.55 to $4.65 and adjusted free cash flow of $270 million or more.
